Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2022-05-19 00:00:00 ET · period of report 2022-05-17 · accession 0001209191-22-030308 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-19 | 2022-05-17 | TEVA | Fridriksdottir Hafrun | Executive VP, Gbl R, D | S - Sale | $8.22 | -130.0K | 1,387 | -99% | -$1.07M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-05-17 | S | D | 130,000 | $8.22 | 1,386.51 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. (F3) The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned. |